1-4 of 4
Andrea Linder
Close
Sort by
Journal Articles

FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience

Huong (Marie) Nguyen, Anh Pham, Cecelia Perkins, Andrea Linder, Lenn Fechter, Jason Gotlib
Journal: Blood
Blood (2012) 120 (21): 1747.
https://doi.org/10.1182/blood.V120.21.1747.1747
Published: 2012
Journal Articles

KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial

Jason Gotlib, Daniel J. DeAngelo, Tracy I. George, Christopher L. Corless, Andrea Linder, Cheryl Langford, Catherine Dutreix, Stefan Gross, Zariana Nikolova, Timothy Graubert
Journal: Blood
Blood (2010) 116 (21): 316.
https://doi.org/10.1182/blood.V116.21.316.316
Published: 2010
Journal Articles

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.

Jason Gotlib, Tracy I. George, Chris Corless, Andrea Linder, Alisa Ruddell, Cem Akin, Daniel J. DeAngelo, Ilana Kepten, Carlo Lanza, Heidrun Heinemann, Ophelia Yin, Neil Gallagher, Tim Graubert
Journal: Blood
Blood (2007) 110 (11): 3536.
https://doi.org/10.1182/blood.V110.11.3536.3536
Published: 2007
Journal Articles

Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.

Jason Gotlib, MD, MS, Tracy I. George, M.D., Andrea Linder, R.N., Alisa Ruddell, R.N., Sylvia Quesada, R.N., Cem Akin, M.D., Daniel J. DeAngelo, M.D.,Ph.D., Pamela Cohen, M.D., Timothy Graubert, M.D.
Journal: Blood
Blood (2006) 108 (11): 3609.
https://doi.org/10.1182/blood.V108.11.3609.3609
Published: 2006